Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

ECOG- ACRIN / EA2182

Trial Overview

Official Title

Study Lower-Dose Chemoradiation for Early-Stage Anal Cancer

Study Purpose

To compare lower-dose chemoradiation therapy to standard-dose chemoradiation therapy and to find out if this approach is better or worse than the usual approach for anal cancer.

Diagnosis

Anal Cancer

Eligibility

Patients can be HIV-positive or HIV-negative.

Patients must have no history of prior radiation or chemotherapy for this malignancy.

Patients must not have had a potentially curative surgery for this cancer prior to enrolling in this study.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Study Treatment: Chemoradiation, which is when you receive both chemotherapy and radiation
  • Group 1: Standard dose of chemoradiation therapy
  •  Group 2: Lower dose of chemoradiation therapy
  • Quality of Life questionnaires
  •  Patients must keep a pill diary.

After completion of chemoradiation therapy, patients will be followed for up to 5 years and watch for side effects, monitor cancer, and complete questionnaires.

For more information, click the link below:

 

https://clinicaltrials.gov/study/NCT04166318?term=EA2182&rank=1

 

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
EA2182
Related Specialties